Attached files

file filename
EX-31.A - EX-31.A - DUSA PHARMACEUTICALS INCy90065exv31wa.htm
EX-32.B - EX-32.B - DUSA PHARMACEUTICALS INCy90065exv32wb.htm
EX-99.1 - EX-99.1 - DUSA PHARMACEUTICALS INCy90065exv99w1.htm
EX-31.B - EX-31.B - DUSA PHARMACEUTICALS INCy90065exv31wb.htm
EX-21.A - EX-21.A - DUSA PHARMACEUTICALS INCy90065exv21wa.htm
EX-23.A - EX-23.A - DUSA PHARMACEUTICALS INCy90065exv23wa.htm
10-K - FORM 10-K - DUSA PHARMACEUTICALS INCy90065e10vk.htm
EXHIBIT 32(a)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the annual report of DUSA Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, Robert F. Doman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
     
Date: March 3, 2011
 
/s/  Robert F. Doman
Robert F. Doman
President and Chief Executive Officer
(principal executive officer)